Profile

Cover photo
Ocata Therapeutics
73 followers|18,876 views
AboutPosts

Stream

Ocata Therapeutics

Shared publicly  - 
 
Ocata Therapeutics Successfully Completes Dosing in Phase 1/2 RPE Studies http://bit.ly/1G3kP4r
MARLBOROUGH, Mass.-- Ocata Therapeutics, Inc. (“Ocata”; NASDAQ:OCAT), a leader in the field of regenerative ophthalmology, today announced that the company has completed dosing of its Phase 1/2 studies for dry age-related macular degeneration (AMD) and Stargardt's Macular Degeneration (SMD).
1
Add a comment...

Ocata Therapeutics

Shared publicly  - 
 
Ocata Therapeutics Receives Regulatory Guidance from European Medicines Agency http://bit.ly/1FviM7t
MARLBOROUGH, Mass.-- Ocata Therapeutics, Inc. (“Ocata”; NASDAQ: OCAT), a leader in the field of regenerative ophthalmology, today announced that the company has received written formal guidance from the European Medicines Agency (EMA) related to the advancement of its Retinal Pigment Epithelium ...
1
Add a comment...

Ocata Therapeutics

Shared publicly  - 
 
Ocata Therapeutics Approved for Listing on NASDAQ http://bit.ly/1LIXyD8
MARLBOROUGH, Mass.-- Ocata Therapeutics, Inc. (“Ocata”; NASDAQ Global Market: OCAT), a clinical stage biotechnology company developing regenerative ophthalmology therapeutics, today announced that it has received notice that the NASDAQ Listing Qualifications Department has approved its ...
1
Add a comment...

Ocata Therapeutics

Shared publicly  - 
 
Ocata Therapeutics to Present at 2015 Cowen Health Care Conference http://bit.ly/1DQD1M1
MARLBOROUGH, Mass.-- Ocata Therapeutics, Inc. (“Ocata”; OTCBB: OCAT), a leader in the field of regenerative ophthalmology, today announced that that Paul Wotton, Ph.D., President and Chief Executive Officer, will present a company overview at the 2015 Cowen Health Care Conference on Tuesday, ...
1
Add a comment...

Ocata Therapeutics

Shared publicly  - 
 
Ocata Therapeutics to Present at 17th Annual BIO CEO & Investor Conference http://bit.ly/1I0DLm5
MARLBOROUGH, Mass.-- Ocata Therapeutics, Inc. (“Ocata”; OTCBB: OCAT), a leader in the field of regenerative ophthalmology, today announced that Paul Wotton, Ph.D., President and Chief Executive Officer, will present a company overview at the 17th Annual BIO CEO and Investor Conference on Monday, ...
1
Add a comment...

Ocata Therapeutics

Shared publicly  - 
 
Ocata Therapeutics Announces Proposed Underwritten Offering of Common Stock http://bit.ly/1CCIdEV
MARLBOROUGH, Mass.-- Ocata Therapeutics, Inc. (OTCBB: OCAT), a clinical stage biotechnology company developing regenerative ophthalmology therapeutics, today announced its intention to offer and sell 10000000 shares of its common stock in an underwritten public offering pursuant to its existing ...
1
Add a comment...
Have them in circles
73 people
James Ketelaar's profile photo
K2 Ocata's profile photo
Alicia Zeedar's profile photo
Tom Wood's profile photo
Auggie L's profile photo
Bruno Yang's profile photo
The DAVIS Companies's profile photo
Jonah Samuels's profile photo
Leslie Girolami's profile photo

Ocata Therapeutics

Shared publicly  - 
 
Ocata Therapeutics Licenses Induced Pluripotent Stem Cell Technology from Allele Biotechnology and Extends Leadership Position in Cell Therapy Capabilities
http://bit.ly/1Hw5GWh
MARLBOROUGH, Mass.-- Ocata Therapeutics, Inc. (“Ocata” or “the Company”; NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, today announced that it has entered into a definitive agreement with Allele Biotechnology & Pharmaceuticals, Inc. of San Diego, CA (“Allele”) to access ...
1
Add a comment...

Ocata Therapeutics

Shared publicly  - 
 
Ocata Therapeutics to Host Conference Call and Webcast to Provide Corporate Update for the Fourth Quarter and Full Year of 2014 http://bit.ly/1GrhGrK
MARLBOROUGH, Mass.-- Ocata Therapeutics, Inc. (“Ocata”; NASDAQ Global Market: OCAT), a clinical stage biotechnology company developing regenerative ophthalmology therapeutics, announced today that it will host a conference call on Thursday, March 12, 2015 at 4:30 p.m. EDT, during which it will ...
1
Add a comment...

Ocata Therapeutics

Shared publicly  - 
 
Ocata Therapeutics Receives Two New Patents for Immune-modulatory Cell Technology http://bit.ly/1DTAVem
MARLBOROUGH, Mass.-- Ocata Therapeutics, Inc. (“Ocata” or “the Company”; OTCBB: OCAT), a leader in the field of Regenerative OphthalmologyTM, today announced that the United States Patent and Trademark Office (USPTO) issued two U.S. Patents, Nos. 8962321 and 8961956, directed to the Company's ...
1
Add a comment...

Ocata Therapeutics

Shared publicly  - 
 
Ocata Therapeutics Withdraws Offering of Common Stock http://bit.ly/1yjtuGF
MARLBOROUGH, Mass.-- Ocata Therapeutics, Inc. (OTCBB: OCAT), a clinical stage biotechnology company developing regenerative ophthalmology therapeutics, today announced that it has withdrawn its previously announced public offering of 10000000 shares of common stock under its shelf registration ...
1
Add a comment...

Ocata Therapeutics

Shared publicly  - 
 
Ocata Therapeutics Appoints John Heffernan, Vice President of Manufacturing http://bit.ly/1x9fEpZ
MARLBOROUGH, Mass.-- Ocata Therapeutics, Inc. (“Ocata”; OTCBB: OCAT), a leader in the field of regenerative ophthalmology, today announced the appointment of John Heffernan, a pharmaceutical industry veteran, to the newly created position of Vice President of Manufacturing.
1
Add a comment...

Ocata Therapeutics

Shared publicly  - 
 
Ocata Therapeutics to Present at 26th Annual Piper Jaffray Health Care Conference http://bit.ly/1CahcZi
MARLBOROUGH, Mass.-- Ocata Therapeutics, Inc., (OTCBB: OCAT) today announced that Paul Wotton, Ph.D., President and Chief Executive Officer, will present a company overview at the 26th Annual Piper Jaffray Health Care Conference on Tuesday, December 2, 2014 at 9:30 a.m. EST in New York City.
1
Add a comment...
People
Have them in circles
73 people
James Ketelaar's profile photo
K2 Ocata's profile photo
Alicia Zeedar's profile photo
Tom Wood's profile photo
Auggie L's profile photo
Bruno Yang's profile photo
The DAVIS Companies's profile photo
Jonah Samuels's profile photo
Leslie Girolami's profile photo
Contact Information
Contact info
Phone
(508) 756-1212
Fax
(508) 229-2333
Address
33 Locke Drive Marlborough, MA 01752
Story
Tagline
Ocata Therapeutics (OTCBB: OCAT) is a clinical stage biotechnology company focused on the development and commercialization of regenerative medicine & cell therapy technologies
Introduction

Ocata Therapeutics, Inc. (“Ocata”; OTCBB: OCAT), formerly named Advanced Cell Technology, is a clinical stage biotechnology company focused on the development and commercialization of new therapies in the field of regenerative medicine. Regenerative medicine is defined as the process of replacing or regenerating human cells, tissues or organs to restore or establish normal function and has been called the “next evolution of medical treatments” and “the vanguard of 21st century healthcare” by the U.S. Department of Health and Human Services.

The company’s principal R&D and commercial efforts relate to its Regenerative Ophthalmology™ programs and involve development of therapies for the treatment of eye diseases and disorders. Beyond the eye, our other research areas include projects focusing on developing many different cell therapies that may be used to treat a range of diseases across several therapeutic categories. Ocata’s principal laboratory, GMP facility and corporate offices are in Marlborough, Massachusetts